| abstract |
Inhibitors of testosterone 5α-reductase activity, for example those of formula (I) wherein novel substituents are provided at the R?4, R6, R7, R17α¿ and/or R17β positions are useful for the treatment of diseases whose progress is aided by activation of androgen receptors, e.g., prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia and the like. |